Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study
Author:
Publisher
Wiley
Subject
Clinical Neurology,Neurology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1528-1167.2008.01946.x/fullpdf
Reference19 articles.
1. Benefit-risk assessment of levetiracetam in the treatment of partial seizures;Abou-Khalil;Drug Saf,2005
2. Eslicarbazepine acetate (BIA 2-093);Almeida;Neurotherapeutics,2007
3. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment;Almeida;Eur J Clin Pharmacol,2008
4. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy;Barcs;Epilepsia,2000
5. Enhanced expression of a specific hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) in surviving dentate gyrus granule cells of human and experimental epileptic hippocampus;Bender;J Neurosci,2003
Cited by 231 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of add‐on antiseizure medications for focal epilepsy: A network meta‐analysis;Epilepsia Open;2024-06-18
2. Highest Dose of Eslicarbazepine for Refractory Secondary Trigeminal Neuralgia;American Journal of Therapeutics;2024-05-02
3. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: A systematic review and network meta-analysis;Seizure: European Journal of Epilepsy;2024-05
4. Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial;Clinical and Translational Science;2024-05
5. Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials;eClinicalMedicine;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3